The ERBB2 (HER2) gene is frequently amplified (24%) in PCa, and it is associated with worse prognosis partly by mediating resistance to gemcitabine and irinotecan/SN-38 treatment [114,115]. Here, ERBB2 is linked to posterior cortical atrophy.